MannKind Corporation (NASDAQ:MNKD) Q2 2025 Earnings Call Transcript
Operator: Good morning, and welcome to the MannKind Corporation Second Quarter 2025 Financial Results Conference Call.
Mannkind Corp (MNKD)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Kapitalo Investimentos Jo„O Carlos Pinho And Carlos Woelz | 13,744 | $51,403 | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.93 | 791 | $2,317.63 | 728,997 | 2022-07-31 | Filing | |
| $2.93 | 3,147 | $9,220.71 | 2,084,486 | 2022-07-31 | Filing | |
| $2.93 | 4,581 | $13,422.33 | 830,650 | 2022-07-31 | Filing | |
| $2.93 | 5,000 | $14,650.00 | 781,690 | 2022-07-31 | Filing | |
| $2.71 | 36,900 | $99,999.00 | 576,690 | 2022-02-28 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.94 | 75,367 | $296,945.98 | 830,508 | 2025-07-16 | Filing | |
| $3.94 | 7,466 | $29,416.04 | 841,719 | 2025-07-16 | Filing | |
| $4.00 | 64,085 | $256,340.00 | 925,258 | 2025-06-10 | Filing | |
| $4.40 | 12,078 | $53,143.20 | 989,343 | 2025-05-20 | Filing | |
| $4.41 | 2,345 | $10,341.45 | 879,546 | 2025-05-20 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 7,617,583 | $28,493,643 | 0% | |
| 2. | 2,582,010 | $9,656,718 | 1.35% | |
| 3. | 8,060 | $8,064,030 | 0.27% | |
| 4. | 1,369,671 | $5,122,570 | 0.02% | |
| 5. | 4,300,000 | $4,329,760 | 0.54% |
News See All
Wedbush Maintains a Buy on MannKind Corporation (MNKD)
MannKind Corporation (NASDAQ:MNKD) is one of the best strong buy penny stocks to buy now.
H.C. Wainwright Affirms MannKind Corp (MNKD)’s ‘Buy’ Rating Buoyed by Product Pipeline
MannKind Corporation (NASDAQ:MNKD) is one of the penny stocks that will skyrocket. On July 16, H.C. Wainwright assumed coverage of the stock with a ‘Buy’ rating and a $9 price target.
Wedbush Remains Bullish on MannKind Corporation (MNKD)
MannKind Corporation (NASDAQ:MNKD) is one of the best biotech penny stocks to buy right now.
14 Best Biotech Penny Stocks to Buy Right Now
He acknowledged that biotech has been a “super tough sector” either way, as there are hundreds of publicly traded stocks that do not add up to anything in aggregate.
10 Penny Stocks That Will Skyrocket
Valuations in the equity markets sit at historical highs, raising questions about future market performance.
RBC Capital Lowered the PT on MannKind Corporation (MNKD), Kept a Buy Rating
MannKind Corporation (NASDAQ:MNKD) is one of the High Growth Penny Stocks That Are Profitable in 2025. On July 23, RBC Capital’s analyst Douglas Miehm lowered the firm’s price target on MannKind ...
7 High Growth Penny Stocks That Are Profitable in 2025
On July 15, Riverwater Partners' Founder and CEO released his quarterly letter and small-cap strategy, highlighting a surprising paradox.
MannKind Corporation (MNKD) Presented Inhaled Insulin Therapy At American Diabetes Association
MannKind Corporation (NASDAQ:MNKD) is one of the Best American Penny Stocks to Buy According to Analysts. MannKind Corporation (NASDAQ:MNKD) presented inhaled insulin therapy at the American Diabetes...
11 Best American Penny Stocks to Buy According to Analysts
On July 19, Bailard released its Q2 2025 Small Cap Value Strategy report. The report highlights that in early April, fears of trade wars pushed the US equity markets near bear market territory.
Billionaire Hedge Funds
